Cytochrome P450 (CYP) 2J2 gene transfection attenuates MMP-9 via inhibition of NF-kappabeta in hyperhomocysteinemia

J Cell Physiol. 2008 Jun;215(3):771-81. doi: 10.1002/jcp.21356.

Abstract

Hyperhomocysteinemia (HHcy) is associated with atherosclerotic events involving the modulation of arachidonic acid (AA) metabolism and the activation of matrix metalloproteinase-9 (MMP-9). Cytochrome P450 (CYP) epoxygenase-2J2 (CYP2J2) is abundant in the heart endothelium, and its AA metabolites epoxyeicosatrienoic acids (EETs) mitigates inflammation through NF-kappabeta. However, the underlying molecular mechanisms for MMP-9 regulation by CYP2J2 in HHcy remain obscure. We sought to determine the molecular mechanisms by which P450 epoxygenase gene transfection or EETs supplementation attenuate homocysteine (Hcy)-induced MMP-9 activation. CYP2J2 was over-expressed in mouse aortic endothelial cells (MAECs) by transfection with the pcDNA3.1/CYP2J2 vector. The effects of P450 epoxygenase transfection or exogenous supplementation of EETs on NF-kappabeta-mediated MMP-9 regulation were evaluated using Western blot, in-gel gelatin zymography, electromobility shift assay, immunocytochemistry. The result suggested that Hcy downregulated CYP2J2 protein expression and dephosphorylated PI3K-dependent AKT signal. Hcy induced the nuclear translocation of NF-kappabeta via downregulation of IKbetaalpha (endogenous cytoplasmic inhibitor of NF-kappabeta). Hcy induced MMP-9 activation by increasing NF-kappabeta-DNA binding. Moreover, P450 epoxygenase transfection or exogenous addition of 8,9-EET phosphorylated the AKT and attenuated Hcy-induced MMP-9 activation. This occurred, in part, by the inhibition of NF-kappabeta nuclear translocation, NF-kappabeta-DNA binding and activation of IKbetaalpha. The study unequivocally suggested the pivotal role of EETs in the modulation of Hcy/MMP-9 signal.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, N.I.H., Intramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • 8,11,14-Eicosatrienoic Acid / analogs & derivatives
  • 8,11,14-Eicosatrienoic Acid / pharmacology
  • Animals
  • Cells, Cultured
  • Cytochrome P-450 CYP2J2
  • Cytochrome P-450 Enzyme System / genetics*
  • Cytochrome P-450 Enzyme System / metabolism*
  • Enzyme Activation / drug effects
  • Enzyme Induction / drug effects
  • Homocysteine / pharmacology
  • Hyperhomocysteinemia / enzymology
  • Hyperhomocysteinemia / metabolism*
  • I-kappa B Proteins / metabolism
  • Matrix Metalloproteinase 9 / biosynthesis
  • Matrix Metalloproteinase 9 / metabolism*
  • Mice
  • NF-KappaB Inhibitor alpha
  • Oxygenases / genetics*
  • Oxygenases / metabolism*
  • Phosphatidylinositol 3-Kinases / metabolism
  • Phosphorylation / drug effects
  • Proto-Oncogene Proteins c-akt / metabolism
  • Transcription Factor RelA / antagonists & inhibitors*
  • Transcription Factor RelA / metabolism
  • Transfection

Substances

  • I-kappa B Proteins
  • Nfkbia protein, mouse
  • Transcription Factor RelA
  • Homocysteine
  • NF-KappaB Inhibitor alpha
  • 8,9-epoxyeicosatrienoic acid
  • Cytochrome P-450 Enzyme System
  • Oxygenases
  • Cytochrome P-450 CYP2J2
  • Proto-Oncogene Proteins c-akt
  • Matrix Metalloproteinase 9
  • 8,11,14-Eicosatrienoic Acid